Dare Bioscience, Inc. Operating Income Loss

• Dare Bioscience, Inc. showed an increase of +42.2% in Operating Income Loss from 2024 to 2025.
• This data is from Dare Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Dare Bioscience, Inc.'s Operating Income Loss has declined by 2,049.1%.
• Historical annual values: Fiscal year 2025: -$13.55 million | Fiscal year 2024: -$23.45 million | Fiscal year 2023: -$30.94 million | Fiscal year 2022: -$31.39 million | Fiscal year 2021: -$39.07 million | Fiscal year 2020: -$27.40 million | Fiscal year 2019: -$14.34 million | Fiscal year 2018: -$16.88 million | Fiscal year 2017: -$11.18 million | Fiscal year 2016: -$630.6 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026